1. Vikkula M, Boon LM, Mulliken JB. Molecular genetics of
vascular malformations. Matrix Biol 2001; 20(5-6):327-35.
2. McCormick WF. The pathology of vascular
(“arteriovenous”) malformations. J Neurosurg 1966;
24(4):807-16.
3. Stein JP, Munjaal RP, Lagace L, Lai EC, O’Malley
BW, Means AR: Tissue-specific expression of a chicken
calmodulin pseudogene lacking intervening sequences.
Proc Natl Acad Sci U S A 1983; 80(21):6485-89.
4. Labauge P, Denier C, Bergametti F, Tournier-Lasserve
E. Genetics of cavernous angiomas. Lancet Neurol 2007;
6(3):237-44.
5. Uranishi R, Baev NI, Ng PY, Kim JH, Awad IA.
Expression of endothelial cell angiogenesis receptors in
human cerebrovascular malformations. Neurosurgery
2001; 48(2):359-67; discussion 367-8.
6. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti
D: Ultrastructural and immunocytochemical evidence
that an incompetent blood-brain barrier is related to the
pathophysiology of cavernous malformations. J Neurol
Neurosurg Psychiatry 2001; 71(2):188-92.
13
Serebral Kavernöz Malformasyonların Moleküler ve Genetik Temelleri
Akd Tıp D / Akd Med J / 2017; 1: 7-14
7. Tanriover G, Sozen B, Seker A, Kilic T, Gunel M, Demir
N. Ultrastructural analysis of vascular features in cerebral
cavernous malformations. Clin Neurol Neurosurg 2013;
115(4):438-44.
8. Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek
L, Steinberg GK, Ogilvy CS, Berg MJ, Crawford SC,
Scott RM, et al. Multilocus linkage identifies two new
loci for a mendelian form of stroke, cerebral cavernous
malformation, at 7p15-13 and 3q25.2-27. Hum Mol
Genet 1998; 7(12):1851-8.
9. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville
JP, Lescoat C, Cecillon M, Marechal E, Joutel A, Bach
JF, Tournier-Lasserve E. Truncating mutations in CCM1,
encoding KRIT1, cause hereditary cavernous angiomas.
Nat Genet 1999; 23(2):189-93.
10. Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA.
Association of Krev-1/rap1a with Krit1, a novel ankyrin
repeat-containing protein encoded by a gene mapping to
7q21-22. Oncogene 1997; 15(9):1043-49.
11. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS.
Vascular morphogenesis: Tales of two syndromes. Hum
Mol Genet 2003; 12(1):97-112.
12. Bouvard D, Vignoud L, Dupe-Manet S, Abed N, Fournier
HN, Vincent-Monegat C, Retta SF, Fassler R, Block MR.
Disruption of focal adhesions by integrin cytoplasmic
domain-associated protein-1 alpha. J Biol Chem 2003;
278(8):6567-74.
13. Moser M, Legate KR, Zent R, Fassler R. The tail of
integrins, talin, and kindlins. Science 2009; 324(5929):
895-99.
14. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN,
Bencharit S, Johnson GL. Rho kinase inhibition rescues
the endothelial cell cerebral cavernous malformation
phenotype. J Biol Chem 2010; 285(16):11760-64.
15. Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL,
Kaibuchi K, Persidsky Y, Ikezu T. Phosphorylation of
claudin-5 and occludin by rho kinase in brain endothelial
cells. Am J Pathol 2008; 172(2):521-33.
16. Schuyler SC, Pellman D. Microtubule “plus-end-tracking
proteins”: The end is just the beginning. Cell 2001;
105(4):421-4.
17. Gunel M, Laurans MS, Shin D, DiLuna ML, Voorhees J,
Choate K, Nelson-Williams C, Lifton RP. KRIT1, a gene
mutated in cerebral cavernous malformation, encodes a
microtubule-associated protein. Proc Natl Acad Sci U S A
2002; 99(16):10677-82.
18. Albelda SM, Muller WA, Buck CA, Newman PJ. Molecular
and cellular properties of PECAM-1 (endoCAM/CD31):
A novel vascular cell-cell adhesion molecule. J Cell Biol
1991; 114(5):1059-68.
19. Reedquist KA, Ross E, Koop EA, Wolthuis RM,
Zwartkruis FJ, van Kooyk Y, Salmon M, Buckley CD, Bos
JL. The small GTPase, Rap1, mediates CD31-induced
integrin adhesion. J Cell Biol 2000; 148(6):1151-58.
20. Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA,
Marchuk DA. KRIT1 association with the integrinbinding
protein ICAP-1: A new direction in the
elucidation of cerebral cavernous malformations (CCM1)
pathogenesis. Hum Mol Genet 2002; 11(4):389-96.
21. Zhang J, Clatterbuck RE, Rigamonti D, Chang DD, Dietz
HC. Interaction between krit1 and icap1alpha infers
perturbation of integrin beta1-mediated angiogenesis in
the pathogenesis of cerebral cavernous malformation.
Hum Mol Genet 2001; 10(25):2953-60.
22. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin
MT, Liao JK. Essential role of endothelial Notch1 in
angiogenesis. Circulation 2005; 111(14):1826-32.
23. Vestweber D, Winderlich M, Cagna G, Nottebaum AF.
Cell adhesion dynamics at endothelial junctions: VEcadherin
as a major player. Trends Cell Biol 2009; 19(1):8-
15.
24. van den Berg MC, Burgering BM. CCM1 and the second
life of proteins in adhesion complexes. Cell Adh Migr
2014; 8(2):146-57.
25. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee
S, Boland P, Gale NW, Lin HC, Yancopoulos GD,
Thurston G. Blockade of Dll4 inhibits tumour growth by
promoting non-productive angiogenesis. Nature 2006;
444(7122):1032-37.
26. Brutsch R, Liebler SS, Wustehube J, Bartol A, Herberich
SE, Adam MG, Telzerow A, Augustin HG, Fischer
A. Integrin cytoplasmic domain-associated protein-1
attenuates sprouting angiogenesis. Circ Res 2010;
107(5):592-601.
27. Wustehube J, Bartol A, Liebler SS, Brutsch R, Zhu Y,
Felbor U, Sure U, Augustin HG, Fischer A. Cerebral
cavernous malformation protein CCM1 inhibits sprouting
angiogenesis by activating DELTA-NOTCH signaling.
Proc Natl Acad Sci U S A 2010; 107(28):12640-45.
28. Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro
C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday
G, et al. EndMT contributes to the onset and progression
of cerebral cavernous malformations. Nature 2013;
498(7455):492-96.
29. Revencu N, Vikkula M: Cerebral cavernous malformation:
New molecular and clinical insights. J Med Genet 2006;
43(9):716-21.
30. Hilder TL, Malone MH, Bencharit S, Colicelli J, Haystead
TA, Johnson GL, Wu CC. Proteomic identification of the
cerebral cavernous malformation signaling complex. J
Proteome Res 2007; 6(11):4343-55.
14
Cici M. ve ark.
Akd Tıp D / Akd Med J / 2017; 1: 7-14
31. Tanriover G, Sozen B, Gunel M, Demir N. CCM2
expression during prenatal development and adult human
neocortex. Int J Dev Neurosci 2011; 29(5):509-14.
32. Huang EJ, Reichardt LF. Trk receptors: Roles in neuronal
signal transduction. Annu Rev Biochem 2003; 72:609-42.
33. Lavoie JF, Lesauteur L, Kohn J, Wong J, Furtoss O, Thiele
CJ, Miller FD, Kaplan DR. TrkA induces apoptosis of
neuroblastoma cells and does so via a p53-dependent
mechanism. J Biol Chem 2005; 280(32):29199-207.
34. Harel L, Costa B, Tcherpakov M, Zapatka M, Oberthuer
A, Hansford LM, Vojvodic M, Levy Z, Chen ZY, Lee
FS, et al. CCM2 mediates death signaling by the TrkA
receptor tyrosine kinase. Neuron 2009; 63(5):585-91.
35. Li X, Zhang R, Zhang H, He Y, Ji W, Min W, Boggon
TJ. Crystal structure of CCM3, a cerebral cavernous
malformation protein critical for vascular integrity. J Biol
Chem 2010; 285(31):24099-107.
36. Fidalgo M, Fraile M, Pires A, Force T, Pombo C, Zalvide J.
CCM3/PDCD10 stabilizes GCKIII proteins to promote
Golgi assembly and cell orientation. J Cell Sci 2010;
123(Pt 8):1274-84.
37. Zhang H, Ma X, Deng X, Chen Y, Mo X, Zhang Y, Zhao
H, Ma D. PDCD10 interacts with STK25 to accelerate cell
apoptosis under oxidative stress. Front Biosci (Landmark
Ed) 2012; 17:2295-305.
38. Louvi A, Nishimura S, Gunel M. Ccm3, a gene associated
with cerebral cavernous malformations, is required for
neuronal migration. Development 2014; 141(6):1404-15.
Thank you for copying data from http://www.arastirmax.com
